Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab

Raphael B. Moreira, Lana Hamieh, Evisa Gjini, Ana Lako, Katherine M. Krajewski, Charles H. Yoon, Patrick A. Ott

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen. Case presentation: Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved complete regression of all metastatic lesions 13 months after the first of two consecutive palliative resections of dominant masses and more than two years after treatment with ipilimumab. Conclusion: The exact cause of our patient's sudden onset of tumor regression remains speculative. We hypothesize that the operative trauma followed by the postoperative infections augmented an innate immune response.

Original languageEnglish
Article number61
JournalJournal for ImmunoTherapy of Cancer
Volume5
Issue number1
DOIs
StatePublished - Jul 18 2017

Keywords

  • Antibody therapy
  • Immune checkpoint blockade
  • Immunotherapy
  • Melanoma
  • PD-1

Fingerprint

Dive into the research topics of 'Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab'. Together they form a unique fingerprint.

Cite this